Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world.

Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Biotechnology

Life Sciences

Therapeutics

Uvax Bio

Ji Li

Deven Sandhu

Pedro Garbes

Ke Li

Kevin O'neill

Jiang Zhu

The Leadership Team at Uvax Bio is responsible for setting the strategic vision and operational direction of the company. They oversee the development and commercialization of innovative vaccine candidates utilizing the patented 1c-SApNP technology, while fostering collaboration across departments to address global health challenges. This team ensures regulatory compliance, drives corporate strategy, and leads vaccine development initiatives to bring effective products to market.

Leadership Team

Research and Development

��

Leadership Team

About

Team members

Other teams at Uvax Bio

Research and Development

��������

Leadership Team

About

Team members

Other teams at Uvax Bio

Research and Development

��